Use of the plasminogen activation system by microorganisms

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 6, 1999, Pages 567-576

  Coleman, James L ^b   Benach, Jorge L ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033486130     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90095-1     Document Type: Article

References (124)

1. 1. Raum D, Marcus D, Alper CA, Levey R, Taylor PD, Starzl TE. Synthesis of human plasminogen by the liver. Science 1980;208:1036-7.
2. 2. Saito H, Hamilton SM, Tavill AS, Louis L, Ratnoff OD. Production and release of plasminogen by isolated perfused rat liver. Proc Natl Acad Sci USA 1980;77:6837-40.
3. 3. Wiman B. Primary structure of peptides released during activation of human plasminogen by urokinase. Eur J Biochem 1973;39:1-9.
4. 4. Collen D, Tytgat G, Claeys H, Verslraete M, Wallen P. Metabolism of plasminogen in healthy subjects: effect of tranexamic acid. J Clin Invest 1972;51:1310-8.
5. 5. Lijnen HR, Collen D. Interaction of plasminogen activators and inhibitors with plasminogen and fibrin. Semin Thromb Hemost 1982;8:2-10.
6. 6. International Committee for Thrombosis and Haemostasis (XXVIIIth Meeting). Fibrinolysis subcommittee; 1982 July; Bergamo, Italy. 1982.
7. 7. Liotta LA, Abe S, Robey PG, Martin GR. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 1979;76:2268-72.
8. 8. Danø K, Andreasen PA, Grøndahl-Hansen J, Krislensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
9. 9. Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 1994;15:25-9.
10. 10. Conese M, Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol 1995;8:365-89.
11. 11. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978;84:573-8.
12. 12. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986;103:2411-20.
13. 13. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994;269:15957-60.
14. 14. Werb Z, Banda MJ, Jones PA. Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages. J Exp Med 1980;152:1340-57.
15. 15. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629-36.
16. 16. Werb Z, Mainardi CL, Vater CA, Harris ED Jr. Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977;296:1017-23.
17. 17. DeClerck YA, Laug WE. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. Enzyme and Protein 1996; 49:72-84.
18. 18. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995;9: 794-807.
19. 19. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995;92:2585-93.
20. 20. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996;87:709-19.
21. 21. Handley MA, Steigbigel RT, Morrison SA. A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. J Virol 1996;70:4451-6.
22. 22. Goto H, Kawaaoka Y. A novel mechanism for the acquisition of virulence by a human influenza virus. Proc Natl Acad Sci USA 1998;95:10224-8.
23. 23. Reddy KM, Markus G. Mechanism of activation of human plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. J Biol Chem 1972; 247:1683-91.
24. 24. Castellino FJ, Sodetz JM, Brockway WJ, Siefring GE Jr. Streptokinase. Methods Enzymol 1976;45:244-57.
25. 25. Radek JT, Castellino FJ. Conformational properties of streptokinase. J Biol Chem 1989;264:9915-22.
26. 26. Cederholm-Williams SA, De Cock F, Lijnen HR, Collen D. Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin. Eur J Biochem 1979;100: 125-32.
27. 27. Lynch M, Littler WA, Pentecost BL, Stockley RA. Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. Br Heart J 1991;66:139-42.
28. 28. Wang X, Lin X, Loy JA, Tang J, Zhang XC. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 1998;281:1662-5.
29. 2-antiplasmin. Thromb Res 1980;17:143-52.
30. 30. Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991;266: 11826-32.
31. 31. Kuusela P, Saksela O. Binding and activation of plasminogen at the surface of Staphylococcus aureus. Increase in affinity after conversion to the Lys form of the ligand. Eur J Biochem 1990;193:759-65.
32. 32. Rabijns A, De Bondt HL, De Ranter C. Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential. Nat Struct Biol 1997;4:357-60.
33. 33. Lack CH. Staphylokinase: an activator of plasma protease. Nature 1948;161:559-60.
34. 34. Sako T, Tsuchida N. Nucleotide sequence of the staphylokinase gene from Staphylococcus aureus. Nucleic Acids Res 1983;11:7679-93.
35. 2-plasmin inhibitor. Biochem Biophys Res Commun 1989; 162:830-7.
36. 36. Christner RB, Boyle MD. Role of staphylokinase in the acquisition of plasmin(ogen)-dependent enzymatic activity by staphylococci. J Infect Dis 1996;173:104-12.
37. 37. Zavizion B, White JH, Bramley AJ. Staphylococcus aureus stimulates urokinase-type plasminogen activator expression by bovine mammary cells. J Infect Dis 1997;176: 1637-40.
38. 38. Boyle MD, Lottenberg R. Plasminogen activation by invasive human pathogens. Thromb Haemost 1997;77:1-10.
39. 39. Lottenberg R, DesJardin LE, Wang H, Boyle MD. Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity. J Infect Dis 1992;166:436-40.
40. 40. Wang H, Lottenberg R, Boyle MD. A role for fibrinogen in the streptokinase-dependent acquisition of plasmin (ogen) by group A streptococci. J Infect Dis 1995;171: 85-92.
41. 41. Wang H, Lottenberg R, Boyle MD. Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Microb Pathog 1995;18:153-66.
42. 42. Schmidt KH, Kohler W. Interaction of streptococcal cell wall components with fibrinogen. I. adsorption of fibrinogen by immobilized T-proteins of Streptococcus pyogenes. Immunobiology 1981;158:330-7.
43. 43. Ryc M, Beachey EH, Whitnack E. Ultrastructural localization of the fibrinogen-binding domain of streptococcal M protein. Infect Immun 1989;57:2397-404.
44. 44. Poirier TP, Kehoe MA, Whitnack E, Dockter ME, Beachey EH. Fibrinogen binding and resistance to phagocytosis of Streptococcus sanguis expressing cloned M protein of Streptococcus pyogenes. Infect Immun 1989;57:29-35.
45. 45. Courtney HS, Li Y, Dale JB, Hasty DL. Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. Infect Immun 1994;62: 3937-46.
46. 46. Boyle MD, Weber-Heynemann J, Raeder R, Podbielski A. Characterization of a gene coding for a type IIo bacterial IgG-binding protein. Mol Immunol 1995;32:669-78.
47. 47. D'Costa SS, Boyle MD. Interaction of a group A Streptococcus within human plasma results in assembly of a surface plasminogen activator that contributes to occupancy of surface plasmin-binding structures. Microb Pathog 1998;24: 341-9.
48. 48. Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-328.
49. 49. Berge A, Sjobring U. PAM, a novel plasminogen-binding protein from Streptococcus pyogenes. J Biol Chem 1993; 268:25417-24.
50. 50. Ben Nasr A, Wistedt A, Ringdahl U, Sjobring U. Streptokinase activates plasminogen bound to human group C and G streptococci through M-like proteins. Eur J Biochem 1994;222:267-76.
51. 51. Wistedt AC, Ringdahl U, Muller-Esterl W, Sjobring U. Identification of a plasminogen-binding motif in PAM, a bacterial surface protein. Mol Microbiol 1995;18: 569-78.
52. 52. Ringdahl U, Svensson M, Wistedt AC, Renn T, Kellner R, Muller-Esterl W, et al. Molecular co-operation between protein PAM and streptokinase for plasmin acquisition by Streptococcus pyogenes. J Biol Chem 1998:273:6424-30.
53. 53. Broder CC, Lottenberg R, von Mering GO, Johnston KH, Boyle MD. Isolation of a prokaryotic plasmin receptor. Relationship to a plasminogen activator produced by the same micro-organism. J Biol Chem 1991;266:4922-8.
54. 54. Lottenberg R, Broder CC, Boyle MD, Kain SJ, Schroeder BL, Curtiss Rd. Cloning, sequence analysis, and expression in Escherichia coli of a streptococcal plasmin receptor. J Bacteriol 1992;174:5204-10.
55. 55. Wang H, Lottenberg R, Boyle MD. Analysis of plasmin (ogen) acquisition by clinical isolates of group A streptococci incubated in human plasma. J Infect Dis 1994;169:143-9.
56. 56. Winram SB, Lotlenberg R. The plasmin-binding protein Plr of group A streptococci is identified as glyceraldehyde-3-phosphate dehydrogenase. Microbiology 1996;142: 2311-20.
57. 57. Winram SB, Lottenberg R. Site-directed mutagenesis of streptococcal plasmin receptor protein (Plr) identifies the C-terminal Lys334 as essential for plasmin binding, but mutation of the plr gene does not reduce plasmin binding to group A streptococci. Microbiology 1998;144:2025-35.
58. 58. Pancholi V, Fischetti VA. A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity. J Exp Med 1992; 176: 415-26.
59. 59. Anda P, Backenson PB, Coleman JL, Benach JL. Epitopes shared by unrelated antigens of Borrelia burgdorferi. Infect Immun 1994;62:1070-8.
60. 60. Anda P, Gebbia JA, Backenson PB, Coleman JL, Benach JL. A glyceraldehyde-3-phosphate dehydrogenase homolog in Borrelia burgdorferi and Borrelia hermsii. Infect Immun 1996;64:262-8.
61. 61. Gebbia JA, Backenson PB, Coleman JL, Anda P, Benach JL. Glycolytic enzyme operon of Borrelia burgdorferi: characterization and evolutionary implications. Gene 1997;188: 221-8.
62. 62. Pancholi V, Fischetti VA. α-Enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 1998;273:14503-15.
63. 63. Eichenbaum Z, Green BD, Scott JR. Iron starvation causes release from the group A streptococcus of the ADP-ribosylating protein called plasmin receptor or surface glyceraldehyde-3-phosphate-dehydrogenase. Infect Immun 1996;64: 1956-60.
64. 64. Ferber DM, Brubaker RR. Plasmids in Yersinia pestis. Infect Immun 1981;31:839-41.
65. 65. Brubaker RR, Beesley ED, Surgalla MJ. Role of pesticin 1 and iron in experimental plague. Science 1965;149: 422-4.
66. 66. Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science 1992;258:1004-7.
67. 67. Sodeinde OA, Goguen JD. Genetic analysis of the 9.5-kilo-base virulence plasmid of Yersinia pestis. Infect Immun 1988;56:2743-8.
68. 68. Sodeinde OA, Sample AK, Brubaker RR, Goguen JD. Plasminogen activator/coagulase gene of Yersinia pestis is responsible for degradation of plasmid-encoded outer membrane proteins. Infect Immun 1988;56:2749-52.
69. 69. McDonough KA, Falkow S. A Yersinia pestis-specific DNA fragment encodes temperature-dependent coagulase and frbrinolysin-associated phenotypes. Mol Microbiol 1989;3:767-75.
70. 70. McDonough KA, Barnes AM, Quan TJ, Montenieri J, Falkow S. Mutation in the pla gene of Yersinia pestis alters the course of the plague bacillus-flea (Siphonaptera: Ceratophyllidae) interaction. J Med Entomol 1993;30:772-80.
71. 71. Sample AK, Fowler JM, Brubaker RR. Modulation of the low-calcium response in Yersinia pestis via plasmid-plasmid interaction. Microb Pathog 1987;2:443-53.
72. 72. Kienle Z, Emody L, Svanborg C, O'Toole PW. Adhesive properties conferred by the plasminogen activator of Yersinia pestis. J Gen Microbiol 1992;138:1679-87.
73. 73. Welkos SL, Friedlander AM, Davis KJ. Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092. Microb Pathog 1997;23:211-23.
74. 74. Parkkinen J, Korhonen TK. Binding of plasminogen to Escherichia coli adhesion proteins. FEBS Lett 1989;250: 437-40.
75. 75. Lahteenmaki K, Westerlund B, Kuusela P, Korhonen TK. Immobilization of plasminogen on Escherichia coli flagella. FEMS Microbiol Lett 1993;106:309-14.
76. 76. Sjobring U, Pohl G, Olsen A. Plasminogen, absorbed by Escherichia coli expressing coli or by Salmonella enteritidis expressing thin aggregative fimbriae, can be activated by simultaneously captured tissue-type plasminogen activator (t-PA). Mol Microbiol 1994;14:443-52.
77. 77. Lahteenmaki K, Virkola R, Pouttu R, Kuusela P, Kukkonen M, Korhonen TK. Bacterial plasminogen receptors: in vitro evidence for a role in degradation of the mammalian extracellular matrix. Infect Immun 1995;63:3659-64.
78. 78. Korhonen TK, Lahteenmaki K, Kukkonen M, Pouttu R, Hynonen U, Savolainen K, et al. Plasminogen receptors. Turning Salmonella and Escherichia coli into proteolytic organisms. Adv Exp Med Biol 1997;412:185-92.
79. 79. Ullberg M, Kronvall G, Karlsson I, Wiman B. Receptors for human plasminogen on gram-negative bacteria. Infect Immun 1990;58:21-5.
80. 80. Ullberg M, Kuusela P, Kristiansen BE, Kronvall G. Binding of plasminogen to Neisseria meningitidis and Neisseria gonorrhoeae and formation of surface-associated plasmin. J Infect Dis 1992;166:1329-34.
81. 81. Eberhard T, Ullberg M, Sjostrom I, Kronvall G, Wiman B. Enhancement of tPA-mediated plasminogen activation by baclerial surface receptors. Fibrinolysis 1995;9:65-70.
82. 82. Virkola R, Lahteenmaki K, Eberhard T, Kuusela P, van Alphen L, Ullberg M, et al. Interaction of Haemophilus influenzae with the mammalian extracellular matrix. J Infect Dis 1996;173:1137-47.
83. 83. Ringner M, Valkonen KH, Wadstrom T. Binding of vitronectin and plasminogen to Helicobacter pylori. FEMS Immunol Med Microbiol 1994;9:29-34.
84. 84. Khin MM, Ringner M, Aleljung P, Wadstrom T, Ho B. Binding of human plasminogen and lactoferrin by Helicobacter pylori coccoid forms. J Med Microbiol 1996; 45:433-9.
85. 85. Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP. Lyme disease-a tick-borne spirochetosis? Science 1982;216:1317-9.
86. 86. Baranton G, Assous M, Postic D. Three bacterial species associated with Lyme borreliosis. Clinical and diagnostic implications. Bull Acad Natl Med 1992; 176:1075-85.
87. 87. Steere AC. Lyme disease. N Engl J Med 1989;321:586-96.
88. 88. Garcia-Monco JC, Benach JL. Lyme neuroborreliosis. Ann Neurol 1995;37:691-702.
89. 89. Garcia-Monco JC, Fernandez-Villar B, Benach JL. Adherence of the Lyme disease spirochete to glial cells and cells of glial origin. J Infect Dis 1989;160:497-506.
90. 90. Thomas DD, Comstock LE. Interaction of Lyme disease spirochetes with cultured eucaryotic cells. Infect Immun 1989;57:1324-6.
91. 91. Szczepanski A, Furie MB, Benach JL, Lane BP, Fleit HB. Interaction between Borrelia burgdorferi and endothelium in vitro. J Clin Invest 1990;85:1637-47.
92. 92. Hechemy KE, Samsonoff WA, Harris HL, McKee M. Adherence and entry of Borrelia burgdorferi in Vero cells. J Med Microbiol 1992;36:229-38.
93. 93. Garcia Monco JC, Fernandez Villar B, Rogers RC, Szczepanski A, Wheeler CM, Benach JL. Borrelia burgdorferi and other related spirochetes bind to galactocerebroside. Neurology 1992;42:1341-8.
94. 3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. Proc Natl Acad Sci USA 1993;90: 7059-63.
95. 95. Galbe JL, Guy E, Zapatero JM, Peerschke EI, Benach JL. Vascular clearance of Borrelia burgdorferi in rats. Microb Pathog 1993;14:187-201.
96. 96. Leong JM, Morrissey PE, Ortega-Barria E, Pereira ME, Coburn J. Hemagglutination and proleoglycan binding by the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1995;63:874-83.
97. 97. Peters DJ, Benach JL. Borrelia burgdorferi adherence and injury to undifferentiated and differentiated neural cells in vitro. J Infect Dis 1997;176:470-7.
98. 98. Isaacs RD. Borrelia burgdorferi bind to epithelial cell proteoglycans. J Clin Invest 1994;93:809-19.
99. 99. Guo BP, Norris SJ, Rosenberg LC, Hook M. Adherence of Borrelia burgdorferi to the proteoglycan decorin. Infect Immun 1995;63:3467-72.
100. 100. Marcus LC, Steere AC, Duray PH, Anderson AE, Mahoney EB. Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. Ann Intern Med 1985;103:374-6.
101. 101. Reznick JW, Braunstein DB, Walsh RL, Smith CR, Wolfson PM, Gierke LW, et al. Lyme carditis. Electrophysiologic and histopathologic study. Am J Med 1986; 81:923-7.
102. 102. de Koning J, Hoogkamp-Korstanje JA, van der Linde MR, Crijns HJ. Demonstration of spirochetes in cardiac biopsies of patients with Lyme disease. J Infect Dis 1989;160: 150-3.
103. 103. van der Linde MR, Crijns HJ, de Koning J, Hoogkamp-Korstanje JA, de Graaf JJ, Piers DA, et al. Range of atrioventricular conduction disturbances in Lyme borreliosis: a report of four cases and review of other published reports. Br Heart J 1990;63:162-8.
104. 104. Klein J, Stanek G, Bittner R, Horvat R, Holzinger C, Glogar D. Lyme borreliosis as a cause of myocarditis and heart muscle disease. Eur Heart J 1991; 12(Suppl D):73-5.
105. 105. Zimmer G, Schaible UE, Kramer MD, Mall G, Museteanu C, Simon MM. Lyme carditis in immunodeficient mice during experimental infection of Borrelia burgdorferi. Virchows Arch 1990;417:129-35.
106. 106. Barthold SW, Persing DH, Armstrong AL, Peeples RA. Kinetics of Borrelia burgdorferi dissemination and evolution of disease following intradermal inoculation of mice. Am J Pathol 1991;139:263-73.
107. 107. Defosse DL, Duray PH, Johnson RC. The NIH-3 immunodeficient mouse is a model for Lyme borreliosis myositis and carditis. Am J Pathol 1992;141:3-10.
108. 108. Barthold SW, deSouza MS, Janotka JL, Smith AL, Persing DH. Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol 1993;143:951-71.
109. 109. Ruderman EM, Kerr JS, Telford SR, Spielman A, Glimcher LH, Gravallese EM. Early murine Lyme carditis has a macrophage predominance and is independent of major histocompatibility complex class II-CD4+ T cell interactions. J Infect Dis 1995;171:362-70.
110. 110. Probert WS, Johnson BJ. Identification of a 47 kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31. Mol Microbiol 1998;30:1003-15.
111. 111. Grab DJ, Givens C, Kennedy R. Fibronectin-binding activity in Borrelia burgdorferil. Biochim Biophys Acta 1998; 1407:135-45.
112. 112. Fraser CM, Casjens S, Huang WM, Sutton GG, Clayton R, Lathigra R, et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 1997;390:580-6.
113. 113. Klempner MS, Noring R, Epstein MP, McCloud B, Hu R, Limentani SA, et al. Binding of human plasminogen and urokinase-type plasminogen activator to the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis 1995;171: 1258-65.
114. 114. Coleman JL, Sellati TJ, Testa JE, Kew RR, Furie MB, Benach JL. Borrelia burgdorferi binds plasminogen, resulting in enhanced penetration of endothelial monolayers. Infect Immun 1995;63:2478-84.
115. 115. Fuchs H, Wallich R, Simon MM, Kramer MD. The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor. Proc Natl Acad Sci USA 1994;91: 12594-8.
116. 116. Coleman JL, Roemer EJ, Benach JL. Plasmin-coated Borrelia burgdorferi degrades soluble and insoluble components of the mammalian extracellular matrix. Infect. Immunology 1999;67:3929-36.
117. 117. Coleman JL, Gebbia JA, Piesman J, Degen JL, Bugge TH, Benach JL. Plasminogen is required for efficient dissemination of Borrelia burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 1997;89:1111-9.
118. 118. Hu LT, Perides G, Noring R, Klempner MS. Binding of human plasminogen to Borrelia burgdorferi. Infect Immun 1995;63:3491-6.
119. 119. Klempner MS, Noring R, Epstein MP, McCloud B, Rogers RA. Binding of human urokinase type plasminogen activator and plasminogen to Borrelia species. J Infect Dis 1996; 174:97-104.
120. 120. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991;266: 12752-8.
121. 121. Lottenberg R, Broder CC, Boyle MD. Identification of a specific receptor for plasmin on a group A streptococcus. Infect Immun 1987;55:1914-8.
122. 2-antiplasmin, PAI-1 and PAI-2. Biochem Biophys Res Commun 1996;219: 690-5.
123. 123. Fuchs H, Simon MM, Wallich R, Bechtel M, Kramer MD. Borrelia burgdorferi induces secretion of pro-urokinase-type plasminogen activator by human monocytes. Infect Immun 1996;64:4307-12.
124. 124. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci USA 1995;92:2909-13.